Incyte (LTS:0J9P) Investments And Advances : $288 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Incyte Investments And Advances?

Incyte's Investments And Advances for the quarter that ended in Mar. 2024 was $288 Mil.

Incyte's quarterly Investments And Advances increased from Sep. 2023 ($154 Mil) to Dec. 2023 ($188 Mil) and increased from Dec. 2023 ($188 Mil) to Mar. 2024 ($288 Mil).

Incyte's annual Investments And Advances declined from Dec. 2021 ($221 Mil) to Dec. 2022 ($134 Mil) but then increased from Dec. 2022 ($134 Mil) to Dec. 2023 ($188 Mil).

Incyte Investments And Advances Historical Data

The historical data trend for Incyte's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Investments And Advances Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Investments And Advances

Get a 7-Day Free Trial

133.66

222.30

221.27

133.68

187.72

Incyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Investments And Advances	Get a 7-Day Free Trial															128.31	170.32	153.66	187.72	287.66

Incyte Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Incyte (LTS:0J9P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (LTS:0J9P) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (LTS:0J9P) Headlines

No Headlines